Utilizing Botulinum Toxin for Managing First Bite Syndrome: An Injection Approach Based on Symptom Localization
By
Rosario Marchese-Ragona
Gianmarco Giunta
Daniela Adamo
Elisabetta Zanoletti
Daniele Manfredini
Domenico Antonio Restivo
July 1, 2026
Clinical Scorecard: Utilizing Botulinum Toxin for Managing First Bite Syndrome: An Injection Approach Based on Symptom Localization
At a Glance
Category Detail
Condition First Bite Syndrome Key Mechanisms Autonomic imbalance leading to exaggerated myoepithelial contraction and acute parotid pain. Target Population Patients with postoperative First Bite Syndrome following head and neck surgery. Care Setting Otolaryngology–Head and Neck Surgery outpatient clinic.
Key Highlights
FBS is characterized by severe unilateral parotid pain triggered by the first bite of food. Botulinum toxin type A (BoNT-A) injections have shown efficacy in reducing pain intensity. The 'Follow-the-Pain' technique is proposed for targeted BoNT-A injection. Guideline-Based Recommendations
Diagnosis
Diagnosis is clinical, based on characteristic features of unilateral parotid pain. Management
BoNT-A injections are recommended for refractory symptoms. Monitoring & Follow-up
Monitor for pain intensity reduction and any adverse effects post-injection. Risks
Potential for inadequate response due to variability in injection techniques and dosing. Patient & Prescribing Data
Patients diagnosed with FBS post head and neck surgery.
BoNT-A injections may provide significant clinical improvement in pain management.
Clinical Best Practices
Utilize ultrasound guidance for BoNT-A injections to enhance targeting accuracy. Consider patient history and surgical background when diagnosing FBS. Related Resources & Content
